LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

LLY

901.94

-1.5%↓

JNJ

240.74

+0.03%↑

ABBV

209.39

+0.63%↑

NVS

150.5

-0.65%↓

MRK

119.79

+0.27%↑

Search

CareDx Inc

Open

SectorGezondheidszorg

17.94 -3.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.7

Max

18.92

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.8M

-4.1M

Verkoop

8.3M

108M

K/W

Sectorgemiddelde

14.645

57.05

EPS

0.12

Winstmarge

-3.79

Werknemers

761

EBITDA

-5.7M

1.5M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+40.13% upside

Dividenden

By Dow Jones

Volgende Winsten

29 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-97M

903M

Vorige openingsprijs

21.38

Vorige sluitingsprijs

17.94

Nieuwssentiment

By Acuity

34%

66%

90 / 350 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mrt 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Infosys Agrees to Acquire Stratus

25 mrt 2026, 23:58 UTC

Winsten

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 mrt 2026, 23:58 UTC

Winsten

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 mrt 2026, 23:57 UTC

Winsten

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 mrt 2026, 23:57 UTC

Winsten

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 mrt 2026, 23:41 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 mrt 2026, 23:41 UTC

Winsten

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 mrt 2026, 23:34 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Declines on Possible Technical Correction -- Market Talk

25 mrt 2026, 22:08 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

25 mrt 2026, 22:08 UTC

Marktinformatie

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 mrt 2026, 21:58 UTC

Marktinformatie

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 mrt 2026, 21:37 UTC

Marktinformatie

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 mrt 2026, 21:14 UTC

Acquisities, Fusies, Overnames

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 mrt 2026, 21:13 UTC

Acquisities, Fusies, Overnames

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 mrt 2026, 21:12 UTC

Acquisities, Fusies, Overnames

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 mrt 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

25 mrt 2026, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

25 mrt 2026, 20:33 UTC

Acquisities, Fusies, Overnames

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 mrt 2026, 20:31 UTC

Winsten

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

40.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25 USD  40.13%

Hoogste 28 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

2

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

90 / 350 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat